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In recent years, it has been an explosion of information regarding the role of various myeloid
cells in liver pathology. Macrophages and dendritic cell (DC) play crucial roles in multiple
chronic liver diseases such as fibrosis and non-alcoholic fatty liver disease (NAFLD). The
complexity of myeloid cell populations and the missing exclusive marker combination make
the interpretation of the data often extremely difficult. The current review aims to sum-
marize the multiple roles of macrophages and DCs in chronic liver diseases, especially
pointing out how these cells influence liver immune and parenchymal cells thereby alter-
ing liver function and pathology. Moreover, the review outlines the currently known marker
combinations for the identification of these cell populations for the study of their role in
liver immunology.
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LIVER AS AN IMMUNE MILIEU
The liver functions as a metabolic center to ensure the proper pro-
cessing of nutrients and the clearance of toxins; yet, plays multiple
roles in systemic immune responses and in immune surveillance.
The liver receives blood from both the systemic circulation and
the intestine that mixes within the liver sinusoids (1). Approx-
imately, two-third of the hepatic blood flow procures from the
oxygen rich arteria hepatica and one-third is from the vena porta
carrying microbial and food-derived antigens and molecules (1,
2). The mixed blood travels through the sinusoids that are special-
ized blood vessels lined by the liver sinusoidal endothelial cells
(LSECs). LSECs assemble a discontinuous endothelium that is
in contact with various passenger and organ-resident immune
cells (3). Besides LSECs, the liver contains other parenchymal cells
such as hepatocytes and hepatic stellate cells (HSCs). The acti-
vation status and extracellular matrix production of HSCs are
critical for the progression of multiple liver diseases (4, 5). Impor-
tantly, these liver parenchymal cells interact with the variety of
immune cells, influence memory T cells, respond to danger sig-
nals, and additionally take on the role of antigen presenting cells
(APCs) within the liver (6, 7). As APCs, they present antigens
Abbreviations: APC, antigen presenting cell; BDL, bile duct ligation; BM, bone
marrow; DCs, dendritic cells; Batf3, basic leucine zipper transcription factor, ATF-
like 3; CCL4, carbon tetrachloride; CCR9, chemokine (C–C motif) receptor 9; CTL,
cytotoxic T lymphocyte; DNGR-1, DC NK lectin group receptor-1; DT, diphtheria
toxin; DTR, diphtheria toxin receptor; ECM, extracellular matrix; FA, fatty acid;
Flt3L, FMS-like tyrosine kinase 3 ligand; GM-CSF, granulocyte macrophage colony-
stimulating factor; HSC, hepatic stellate cells; HL-DC, high-lipid liver dendritic cell;
Id2, inhibitor of DNA binding 2; IL, interleukin; KC, Kupffer cells; LL-DC, low-lipid
liver dendritic cell; LSEC, liver sinusoidal endothelial cells; LPS, lipopolysaccha-
ride; MCD, methionine choline deficient; MCP-1, monocyte chemotactic protein-1;
MMP-9, matrix metalloproteinase-9; MMP13, matrix metalloproteinase-13; NASH,
non-alcoholic steatohepatitis; pDC, plasmacytoid dendritic cell; PDL-1, programed
cell death 1 ligand; TNFα, tumor necrosis factor-alpha; TAA, thioacetamide; TLR,
toll like receptor; zbtb46, zinc finger and BTB domain containing.
in the context of immunosuppressive cytokines and inhibitory
surface molecules resulting largely in tolerance (6, 7). The liver
also encompasses large populations of hematopoetic cells such as
innate lymphocytes (NK, NKT cells, and γδT cells) and myeloid
cells [dendritic cells (DCs) and macrophages] (6). Multiple cross-
talks exist between hematopoetic cells and liver parenchymal cells
at steady state and during injury. This review focuses on the phys-
iological and pathological roles of liver DCs and macrophages
paying special attention to chronic liver diseases such as fibrosis
and non-alcoholic fatty liver disease (NAFLD).
LIVER DENDRITIC CELLS
Dendritic cells are present in all tissues and represent the major
APCS within the body (8). They constantly sense their environ-
ment and capable of recognizing pathogens and various danger
signals. Activation of DCs results in their maturation toward
several functionally distinct “effector DCs” (9) that drive T cell
responses, such as T helper cell differentiation, induction of CTL,
and T cell tolerance (9). Additionally, DCs communicate with
innate lymphocytes (e.g., NK, NKT cells), therefore, can influence
both innate and adaptive immune responses (8).
Murine liver DC population, similarly as in most non-
lymphoid organs (except the lamina propria and dermis), consists
of three types of DCs (Table 1): the cDC1s (classical type 1 DCs),
the cDC2s (classical type 2 DCs), and pDCs (10, 11). Despite of
this categorization, in most liver studies, DCs are evaluated as
either CD11c+ or MHCII+ cells. Although neither of the mole-
cules pinpoint exclusively DCs, using these markers liver DCs are
primarily located within the portal area and rarely scattered within
the parenchyma (6). The cDC1 cells resemble lymphoid tissue
CD8+ DCs, show migratory capacity in various non-lymphoid
organs, and can efficiently cross-present cell-associated antigens
(10, 11). Although the role of DC migration in liver pathology has
not been explored in details, antigen injected or targeted to the
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Table 1 | Summary of DC and macrophage population in healthy and injured liver.
Cell types Murine Human Reference
Dendritic cells
Classical Type 1 DCs (cDC1) CD45+ PDCA1− CD11c+ CD11b− CD103+ MHCII+
Langerin+/− F4/80− CX3CR1−
CD45+ HLA-DR+ CD141+ CD123− CD11c+
CD14−
(8, 15)
Classical Type 2 DCs (cDC2) CD45+ PDCA1− CD11c+ CD11b+ CD103− MHCII+
F4/80+/− Langerin− CX3CR1+
CD45+ HLA-DR+ CD1c+ CD123− CD11c+
CD141− CD14+
(10, 15–17)
pDCs CD45+ PDCA1+ CD11c+ HLA-DR+ CD123+ CD11c− CD303+ CD304+ (17)
pre-DCs CD45+ CD11c+ MHCII− Flt3+/− ND (18)
Macrophages
KCs CD68+ F4/80+ CD11blow Ly6Clow Ly6G− TLR4+ TLR9+ CD68+ (19–22)
Ly6Chi classical monocytes F4/80+ CD11bhi Ly6Chi Gr1+ CX3CR1+ CCR2+ CD14hi CD16− (23, 24)
M1 inflammatory
macrophages/monocytes
F4/80+ CCR9+ iNOS+ galectin-3+ CD14+ CD16+(it is not yet clarified how they
differ from non-classical monocytes)
(25–27)
Restorative macrophages F4/80+ CD11blow Ly6Clow CD14+ CD16+ (24, 26, 28)
DCs and macrophages are classified according to the recently suggested nomenclature based on the ontogeny of these cells (15).The M1 type monocyte/macrophage
population present in liver injury and the restorative macrophages during resolution could not be incorporated in this nomenclature as their origin and relation to
monocytes and resident liver macrophages (KCs) need further clarification in the future. DCs, dendritic cells; KCs, Kupffer cells; pDCs, plasmacytoid DCs; pre-DCs,
precursor DCs.
liver reaches the draining LN and induces T cell activation (12,
13). Additionally, migratory DCs could be identified within the
portal lymphatic vessels in electronmicroscopy analyses (1, 14).
The cDC2s within non-lymphoid organs are heterogeneous
and partially monocyte lineage derived (10, 11). Their specific
role is less understood in non-lymphoid organs, involving the
liver as well. While the development of this subset depends in
most non-lymphoid organs on the presence of FLT3L and M-
CSF, in the liver, these cells are not exclusively dependent on these
growth factors but yet on an unidentified molecule (10). The liver,
similarly to other non-lymphoid tissues, contains not only fully
differentiated DCs but precursor DC population as well. From
these pre-DCs, either FLT3L or GM-CSF can induce liver DC
development bestowing DC homeostasis in situ (29, 30).
Functionally, CD11c+ cells isolated from healthy mouse
liver are less mature, have lower capacity to endocytose anti-
gen, and induce less efficient allogenic T cell activation as
secondary lymphoid organ (SLO)-derived DCs (31, 32). The
inhibitory/tolerogenic capacity of liver DCs could be attributed
to the specific microenvironment provided by parenchymal cells
of the liver. Fibroblastic and VCAM+ cells derived from the liver
could induce hematopoetic progenitor cells to differentiate toward
tolerogenic DCs in vitro that can inhibit experimental autoim-
mune hepatitis (33). It is assumed that circulatory DCs during
their translocation within the liver sinusoids toward the lymphat-
ics receive such tolerogenic education from liver parenchymal cells
(14, 34). Yet, its in vivo relevance needs to be elucidated.
Freshly isolated murine liver CD11c+ cells promote Th2 rather
than Th1 T cell differentiation and via interacting with NK cells
induce regulatory T cell (Treg) development (35, 36). Moreover,
liver DCs produce increased amount of IL-10, IL-27 but less IL-12
upon LPS stimuli (37, 38). This hyporesponsive behavior toward
TLR stimuli, known as endotoxin tolerance, involves LPS/TLR4
but also extends toward other TLRs (6). This is especially impor-
tant, as the liver is constantly exposed to gut derived microbial
products. The breakdown in this tolerance could be observed
in colitis where pro-inflammatory DC/macrophage population
expands within the liver due to the increased amount of bacterial
products present in the portal blood. This creates an inflammatory
environment in the liver despite the absence of direct liver dam-
age (39). The tolerant state toward TLRs is an active process and
involves the action of various negative regulators of the TLR signal-
ing pathway (6). Interestingly, under steady state, liver DCs rather
respond to ECM stimuli (collagen-type I, laminin, fibronectin)
that induces MHC-II upregulation and maturation of GM-CSF
expanded liver DCs in vitro (40).
In humans, the cDC2 cells (CD11c+ BDCA1+) are the most
abundant in the liver and they exhibit similar immature, tolero-
genic capacity as their murine counterpart (16, 41) (Table 1). The
cDC1 cell population that expresses CD141+ has been recently
identified as a counterpart of murine CD8α+ cells (42). These
cells induce pro-inflammatory allogeneic MLRs, resulting in IFN-
γ and IL-17 production by activated T cells (17). Importantly,
as opposite to cDC2s and pDCs, cDC1s (identified in the study
as CD141+ cells) were markedly decreased during liver diseases
but among the DC-subsets produced the highest level of IFN-λ
(17). It is possible that functional differences are reflected among
the DC subsets and each subset represents different aspects of
liver immunity and tolerance. In line with this, a classification of
murine liver DCs according to their lipid content distinguishes
between immunogenic and tolerogenic liver DCs. Due to their
acetyl-CoA carboxylase activity, HL-DCs (high lipid DCs) mount
strong immunogenic CTLs while the LL-DCs (low lipid DCs) with
low lipid content are tolerogenic (43). Notably, the marker combi-
nations used for this study showed that both HL-DCs and LL-DCs
include multiple DC-subsets distinguished by currently known
Frontiers in Immunology | Antigen Presenting Cell Biology April 2015 | Volume 6 | Article 179 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eckert et al. Myeloid cells in the liver
surface markers and were not restricted to one specific subset.
Novel surface molecules are needed to specifically explore their
functional diversity.
pDCs are the major source of type-I IFN, regulate NK cell activ-
ity, and play important role in the induction of antiviral immunity
(44, 45). The murine liver is especially rich in pDCs; yet, the
human counterpart contains a smaller proportion of this popula-
tion among all DCs (17) (Table 1). Under steady state condition,
pDCs express low level of costimulatory molecules, are weak T
cell stimulators, and induce apoptosis in activated T cells in a Treg
dependent manner (46). Later could indicate a cellular interplay
between pDCs and Tregs in the liver microenvironment in order
to maintain the tolerogenic milieu. Accordingly, pDCs can induce
efficient CD4 and CD8 T cell tolerance to orally administered
antigens (47).
Microbial products, such as muramyl dipeptide present in
the portal blood, upregulate PDL-1 in pDCs and reduce their
response to TLR9 stimuli (48). This is another example for the
TLR-mediated hyporesponsiveness (“endotoxin tolerance”) in the
liver. Strikingly, upon FLT3L treatment, the expanded liver pDCs
display strong immunostimulatory properties (49). It is unclear
whether this could be due to the expansion of a specific subpopula-
tion of pDCs, or their modified interaction with Tregs, or the result
of the complete rearrangement in the myeloid cell compartment,
and the consequent imbalance in the tolerogenic milieu.
Taken together, the multiple DC subsets within the liver par-
ticipate in guarding the tolerogenic environment and primarily
skewed toward suppressing T cell responses and toward induction
of Tregs. While DCs are the main APCs and inducers of T cell
immunity in SLOs, within the liver environment the question still
remains: how immunity can be induced by DCs in such suppressive
microenvironment? Induction of immunity might be attributed to
special DC subpopultaions such as the CD141+ cDC1s in humans
(17) and the CD103+ cDC1s in mice (50). Moreover, the appear-
ance of novel DC population, such as monocyte-derived DCs
present in iMATEs (intrahepatic myeloid-cell aggregates for T
cell population expansion), participates in efficient CLT expan-
sion within the liver (51). Alternatively, immunity is induced by
migratory DCs reaching the draining LN, thus, outside of the
liver suppressive environment. In line with this, antigen specifi-
cally expressed in draining LN results in hepatitis inducing CD8
T cell activation, while the same antigen within the liver induces
tolerance (52). Additionally, the liver can provide newly formed
structures for T cell activation resulting in immunity. Portal tract
associated lymphatic structures (PALPs) during Propionibacterium
acnes granuloma formation and tertiary lymphoid structures in
biliary cirrhosis represent locations where possible T and B cell
activation takes place, respectively (53, 54).
KUPFFER CELLS – RESIDENT MACROPHAGE POPULATION OF
THE LIVER
Kupffer cells (KCs) are tissue resident macrophages and they rep-
resent the largest hematopoetic cell population within the liver.
They arise from yolk sac during fetal development (55), adjust
themselves to the local microenvironment (56, 57), and renew
their population at steady state locally throughout adult life with
no or minimal contribution of hematopoetic progenitors or blood
monocytes (58–60). In mice, KCs can be distinguished from
monocytes among the F4/80+ cells as Ly6Clow CD11blow cell pop-
ulation (20, 21) (Table 1) and possess functional specifications
according to their positioning within the sinusoid (61). Recent
study could distinguish two KC functional groups: the one with
higher phagocytosis capacity and the one with preference toward
cytokine production (61, 62). Additionally, macrophages are func-
tionally grouped into two classes M1 and M2. While such plain
classification is questionable and often overstated, still provide a
simple but distinguishable concept for functional categorization
of these cells. M1 (termed classically activated) macrophages are
pro-inflammatory, while the M2 (termed alternatively activated)
macrophages are suppressive and involved in cellular repair (63).
According to this, KCs belong to the M2 type of cells and play
fundamental role in homeostasis, immune surveillance, and tissue
repair (63).
Their importance as tolerogenic APCs in the liver microen-
vironment is demonstrated in liver transplantation where they
prolong allograft survival (31). At steady state, they inhibit DC
mediated T cell activation within the sinusoids and presentation
of high affinity peptide by KCs results in deletional CD8 T cell tol-
erance (6, 64). Furthermore, they promote the suppressive capacity
of Tregs toward hepatic antigens (65, 66).
As all tissue resident macrophages, KCs express a wide reper-
toire of receptors for the recognition of pathogens and danger
signals such as Toll-like receptors, members of the inflammasome,
and scavenger receptors (31). In the presence of TLR ligands such
as LPS and CpG, KCs become immunogenic, and can induce CD8
T cell activation, and the generation of efficient CLT response (67,
68). Thus, during liver infection, they support the development
of antimicrobial T cell responses. Unfortunately, KCs induce effi-
cient CTL against antigens from the systemic circulation such as
the case in influenza infection (69). This CTL response results in
bystander hepatitis, often accompanying systemic viral infections.
Besides CD8 T cell responses, recent study describes naive CD4 T
cell activation in the murine liver by antigens expressed in hepa-
tocytes. This process is independent from lymphoid tissue but
dependent on clodronate-sensitive liver APC population possibly
involving KCs as well (70). Thus, KCs participate in the generation
of both CD4 and CD8 T cell responses.
Using their scavenger receptor repertoire, KCs are involved in
the clearance of apoptotic cell debris and central to iron home-
ostasis (71). KCs interact with multiple immune cells within the
sinusoids, such as Tregs, DCs, DC precursors, and innate lym-
phocytes (7, 53, 72, 73). After recognizing any danger signals,
KCs primarily drive the influx of inflammatory leukocytes such
as neutrophils and monocytes (63). Thus, KCs function as sen-
tinels and central orchestrators of cellular processes in healthy
and injured liver. Additionally, while they support the tolerogenic
milieu within the liver, their presence also ensures the protection
of the liver during pathogen invasion.
TOOLS TO STUDY LIVER DCs AND MACROPHAGES
In order to characterize the specific physiological and pathologi-
cal roles of DCs and macrophages, various animal models, tools
have been developed (Table 2) Among these models, there are
mouse lines deficient in transcription factors that are responsible
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Table 2 | Summary of the available models to study liver macrophages and DCs.
Animal model Cell types affected Liver fibrosis/NASH studies
Transcription factors
Cfsr1op/op, Cfsr1−/−, Csfr2−/− Macrophages, monocytes, some DCs, granulocytes ND
Batf3−/−, ID2−/−, IRF8−/− CD8+ DCs, CD103+ DC ND
Flt3L−/−, injection of FLT3L CD8+ CD11b−, CD11b+ DCs, pDCs (75)
IRF2−/−, IRF4−/− CD8− CD11b+ DCs ND
DTR system
CD11c-DTR-short promoter-long promoter DCs, plasmablast, some activate CD8 T cells, marginal zone
macrophages, alveolar macrophages, some B cells
(75–78)
All above + some NK and NKT, pDCs, monocyte-derived DCs
CD11b-DTR Neutrophils, monocytes, eosinophils, macrophages, some DCs (28, 79, 80)
CD169-DTR Splenic MM macrophages, LN macrophages, BM macrophages, KC ND
Langerin-DTR Langerin+ dermal DCs, langerhans cells, some CD8+DCs, and some
CD103+ DCs
ND
Zbtb46-DTR DCs and DC committed progenitors, monocytes (IL-4 and GM-CSF) ND
Clodronate liposome mediated cell
depletion
Macrophages, some DCs, monocytes (81–86)
Reporter/Cre mouse lines
CX3CR1-GFP Macrophages, monocytes, some DCs (87, 88)
Cfsr1-GFP (MacGreen) Macrophages, monocytes, some DCs
Lyz2-GFP/Lyz2-Cre Macrophages, granulocytes
Cfsr1-GFP Macrophages, monocytes, some DCs
CCR2-RFP Monocytes, macrophages, memory T cells
MHCII-EGFP Macrophages, DC, B cells
CD11c-YFP/CD11c Cre See above
Langerin-GFP See above
DNGR-1-GFP DCs, pre-DCs
ND, non-determined; DCs, dendritic cells; MM, marginal zone.
for the development of one or multiple subsets of myeloid cells.
Due to the multiple cell types affected in these models, the broader
impact of each of these genes makes it difficult to unequivocally
pinpoint subset specific functions. Nevertheless, these transgenic
animals helped significantly to establish broader understanding
of macrophage and DC development and their role under steady
state and inflammation (63, 74). However, just few of these models
have been evaluated so far in fibrosis and non-alcoholic steatohep-
atitis (NASH) models (Table 2) but also in liver immunology. This
might extend in the future as genetic model lacking cDC1s have
just recently demonstrated that cDC1s respond to hepatotropic
viral infection and are keys in the induction of anti-viral CD8 T
cell response in situ (50).
The most frequently used cell-depleting tools in liver
immunology are the clodronate liposome mediated depletion of
mononuclear cells and the CD11c-/CD11b-DTR (diphtheria toxin
receptor) transgenic system (87, 89). Clodronate-encapsulated
liposomes are taken up by mononuclear cells and the clodronate
bisphosphonate within the cell induces apoptosis that results in
depletion of the phagocytic cell population. Multiple phagocytic
cell types are affected using this depletion method such as KCs,
macrophages, and some members of the DC population as well.
Since more than one cell types are affected, the effects can be
extrapolated to a group of cells and not to individual subtypes
(89). Additionally, the release of inflammatory mediators (such as
TNF) has been associated with this type of cell depletion further
complicating the interpretation of experimental results (90).
The other widely used tool for liver biology is the CD11c-
DTR-based depletion system. Here, the human diphtheria toxin
receptor is expressed under the CD11c promoter and adminis-
tration of diphtheria toxin results in the depletion of CD11c+
cells. This model is used to dissect the role of conventional DCs.
The major disadvantage in this system is that multiple cell types
are affected such as marginal zone macrophages, monocytes, acti-
vated CD8 T cells, NK cells, and plasmacytoid DCs (89). Two
different CD11c-DTR mouse lines have been generated: the one
encompassing only a short piece of the CD11c promoter (3) and
the one with the full-length promoter (91). Although, they dif-
fer in the list of affected cell types, they gave important insights
in the role of CD11c+ cells in liver immunology (Table 2).
Novel DTR tools have been developed in recent years that aim
to restrict the expression of DTR more specifically to DCs. The
zbtb-46-DTR model uses the transcription factor zbtb46 that
is exclusively expressed by DCs and DC-committed precursors
(92). Unfortunately, zbtb46 is upregulated in monocytes stim-
ulated with GM-CSF and IL-4, suggesting some limitations to
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this promoter (93, 94). Another promising promoter is the DC
NK lectin group receptor-1 (DNGR-1) that seems to be highly
restricted to the DC linage (95). Not only for DCs but also for
the study of macrophages, the perfect targeting tool still needs
to be developed. The primary tool for analyzing macrophages is
the CD11b-DTR system. However, CD11b is a widely expressed
marker among multiple immune cell types causing caveat for the
interpretation of cell types using this model for understanding
liver diseases (Table 2) (87).
To follow myeloid cells in situ using in vivo imaging, flow
cytometry or microscopy multiple reporter mouse models have
been developed. The promoters from different molecules such as
e.g., CD11c, Csfr1, CCR2, MHC-II, or CX3CR1 were used to gen-
erate these animal models (88) (Table 2). These models have their
own limitations according to their expression profile that have
been reviewed elsewhere (88) (Table 2). Some of the promoters
are also utilized to express Cre recombinase (Table 2). Crossing
these Cre expressing lines with animals carrying a flox-ed gene
allows the analyses of the cell specific depletion of the gene of
interest. Certainly, the specificity and limitation of the models are
determined by the expression pattern of the promoter used for
Cre expression (87). Despite the availability of these models, only
limited have been exploited for understanding specifically liver
fibrosis and NASH (Table 2).
Taken together, multiple models are available to answer liver
immunological questions. While each of the available models
has its own limitation, the combination of these models with
each other can still pinpoint important contribution of DCs and
macrophages in liver pathology.
THE ROLE OF DENDRITIC CELLS AND MACROPHAGES IN
CHRONIC LIVER DISEASES
LIVER FIBROSIS PROGRESSION
Liver fibrosis is a common endpoint of many chronic liver dis-
eases such as viral hepatitis, primary biliary cirrhosis, alcoholic and
NASH, or autoimmune liver disorder (96, 97). To investigate liver
fibrogenesis, several rodent models have been developed inducing
toxic (CCL4), biliary (bile duct ligation), oxidative (TAA-induced),
or metabolic (MCD/methionine choline deficient diet induced)
liver damage (96, 97). The MCD diet contains high sucrose and
fat (usually 40% sucrose and 10% fat) but lacks the amino acid
methionine and the small molecule choline that are essential for
hepatic β-oxidation and production/secretion of very low density
lipoprotein (VLDL). As a result, lipids are deposited in the liver
and steatosis, and NASH develops in these animals (98).
Remarkably, even though the molecular mechanisms leading
to hepatic cell death are very different, the process of fibrogenesis
and the cellular components involved share common hallmarks.
Such common components, that have established their role in
liver fibrosis, are the macrophages and the recruited inflammatory
monocytes.
Major evidence for the involvement of macrophages in liver
fibrosis is demonstrated in in vivo depletion studies using the
CD11b-DTR system and the clodronate-liposome mediated cell
depletion. In CCL4 induced liver injury, the progression of fibrosis
was attenuated in the absence of CD11b+ cells and the num-
ber of HSC-derived myofibroblasts was greatly reduced (79).
The administration of clodronate liposomes similarly suggested
that macrophages are pro-fibrogenic and affect the survival of
HSCs via TNF and IL-1 induced NF-kb signaling (84, 99).
Liver macrophage populations change during liver injury. One
of the major changes is the recruitment of inflammatory mono-
cytes to the injured liver and their differentiation toward tissue
macrophages (24, 26, 28, 100). Resident KCs in liver injury rapidly
secrete pro-inflammatory cytokines such as IL-1β, TNF, CCL2, and
CCL5 resulting in recruitment of multiple immune cells involv-
ing monocytes as well. The accumulation of circulating Ly6Chi
monocytes within the liver is greatly dependent on CCR2/CCL2
and CCL1/CCR8 axis (100). The monocyte recruiting chemokines,
however, not only originate from KCs but also from TLR-
activated HSCs (101). Moreover, senescent hepatocytes and NF-
kb-inducing kinase (NIK) activation in hepatocytes lead to the
release of numerous chemokines (86, 102). These chemokines
can influence the migration or activation state of macrophages
that in turn induce hepatocyte apoptosis. Accordingly, hepatocyte-
specific expression of the NIK in vivo triggers massive liver
inflammation and hepatocyte apoptosis leading to liver fibrosis
(86). Thus, the macrophage–hepatocyte cross-talk seems to greatly
influence cell recruitment and the activation state of macrophages,
thereby affecting the progression of liver injury. The fact that in the
above study KC/macrophage depletion using clodronate reversed
NIK-induced damage, also strongly suggests this.
Monocyte recruitment to the injured liver can be observed
early within 24 h after the induction of CCL4 damage (25).
These early recruited cells are CCR9+, colocalize and interact
with CCR9+ HSCs (27). Furthermore, these monocyte-derived
macrophages are characterized as CD11b+F4/80+iNOS+ cells that
exhibit profibrogenic properties via promoting HSC activation,
Th1 cell differentiation, and TGFβ release (25, 26). In addition to
this, profibrogenic Ly6Chi macrophages express PDGF, IL-13 and
IL-4 that directly act on HSC derived myofibroblasts and induce
ECM production (25, 26). Macrophages produce various lectins
among them galectin-3 is required for TGFβ mediated myofibrob-
last activation and matrix production that further underline their
profibrogenic capacity (103).
Another chemokine that affects the infiltrating monocytes is the
fractalkine receptor (CX3CR1). Fractalkine is released by hepa-
tocytes and HSCs during liver injury. It ensures the survival of
infiltrating monocytes and influences their differentiation toward
tissue macrophages (25). In the absence of CX3CR1, infiltrat-
ing monocytes develop into highly inflammatory macrophages
that die early via apoptosis. This perpetuates further inflamma-
tion and recruitment of Ly6Chi cells. Additionally, CX3CR1 on
KCs increase their IL-10 expression and reduces their TNF and
TGFβ (104). Thus, fractalkine represent a negative feedback on
the extension of liver inflammation through affecting KCs and the
presence and destiny of Ly6Chi cells at least in the murine system.
It requires future research to clarify how the changes in monocyte
and macrophage subsets observed in mice are reflected in humans.
Regarding the M1–M2 classification of macrophages, during
the progression phase of liver fibrosis and during fibrosis reso-
lution, both types of cells are present in the liver side by side
(105). Interestingly, based on histological analyses these M1 and
M2 macrophages localize near to the fibrotic septa and could
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indicate further undiscovered cross-talk among these cells in liver
pathology. Of note, transcriptional analyses of macrophages that
are present in the resolution phase display a profile that cannot be
classified according to the M1/M2 nomenclature (28).
Accumulation of macrophages within the injured liver caused
just partially by the recruited monocytes and their differentiation
toward tissue macrophages. There is some evidence that local mul-
tiplication of resident and monocyte-derived macrophage pop-
ulation contribute to this process. Ki67 staining during CCL4
mediated liver injury demonstrated the presence of proliferating
KCs and monocyte-derived macrophages (28, 62). In most recent
study, Listeria infection of the liver resulted in monocyte-derived
macrophage proliferation via IL-4 and IL-33 (106). Whether these
cytokines are also involved in this process during other types of
liver injury and in humans as well remain to be elucidated.
Multiple animal studies reported that the number of dendritic
cells, pre-DCs, and pDCs increase during the progression phase
of liver fibrosis (76, 107). This raised the assumption that DCs
might contribute to fibrosis progression. Using the CD11c-DTR
model, it has been demonstrated that CD11c+ cells provide a pro-
inflammatory milieu by producing IL-1β and TNF during injury
(76). Moreover, isolated cells contribute to HSC survival in vitro
suggesting a clear profibrogenic capacity of these cells (37). This
phenomenon, despite of the relatively broad CD11c expression
among other myeloid cells as discussed above (Tables 1 and 2),
was attributed to DCs.
Another study determined using the same CD11c-DTR system
that DC depletion accelerates the development of fibrosis due to
their influence on angiogenesis. DCs seem to be the source of the
anti-angiogenic VEGF receptor 1 (also known as sFlt-1) and thus
influence the bioavailability of VEGF during fibrogenesis (78).
Notably, recent study has demonstrated that VEGF+ inflamma-
tory monocytes/monocyte derived macrophages colocalize with
newly formed vessels in injured liver and pharmacological inhibi-
tion of CCL2 mediated recruitment of inflammatory monocytes
reduces fibrosis-induced angiogenesis without affecting fibrosis
progression (108). Thus, recruited monocytes/macrophages seem
to counterbalance the anti-angiogenic property of DCs during
fibrosis progression. Whether classical DCs or pDCs truly con-
tribute to fibrosis progression or play other role during liver injury
still remain to be clarified in the future.
LIVER FIBROSIS REGRESSION
During liver fibrosis, the increased production of ECM is accompa-
nied by high expression of MMPs and the presence of collagenase
activity, suggesting alterations and adjustments in the fibrotic
ECM. In fact, the fibrotic ECM seems to be different biochem-
ically than ECM produced during a steady state turnover (109).
In lung fibrosis, the pathological ECM activates fibroblastic cells
to build further matrix indicating a positive cross-talk between
fibroblast and matrix components (109). Also during liver fibro-
sis, heavily cross-linked, modified ECM could be identified (110);
however, it remains to be elucidated whether similar regulatory
loop as in the lung operates in liver fibrosis as well.
Importantly, after removal of the noxious agents causing liver
damage, fibrotic scars degrade and normal liver architecture can be
restored. This process is called resolution. While this functions well
in various animal models, in humans this seems to be a point of
no return where fibrosis and cirrhosis progresses nonetheless (97).
In resolution, the role of macrophages has been demonstrated
in multiple animal studies. Depletion of CD11b+ cells during
fibrosis progression, as above discussed, reduced scarring while
during fibrosis resolution led to a failure in matrix degrada-
tion (79, 80). This strongly suggests the dominant presence of
two functionally different macrophage populations. According to
this, Ramachandran et al. have identified a subset of Ly6Clow
“restorative” macrophages during resolution (28). These cells
originated from Ly6Chi recruited monocytes expressed MMPs
including MMP9,MMP12,and phagocytosis related genes. Impor-
tantly, based on gene expression profiling, they could not be fit
in the M1/M2 macrophage classification. Moreover, phagocyto-
sis of liposomes or cellular debris by liver macrophages could
recapitulate this type of restorative phenotype (28). In addition
to this, recent study demonstrated that scar associated myeloid
cells attract endothelial cells to the scar tissue via VEGF and
that genetic ablation of VEGF in myeloid cells resulted in the
increase of MMP2 and MMP13 and decrease of TIMP1 in the
liver. While macrophages have not been unequivocally identi-
fied as myeloid cells in this study, the results indicate that the
myeloid cells induced angiogenesis gears the balance toward fibrol-
ysis (111). This is in line with recent findings that demonstrated
that VEGF signaling plays key role during liver fibrosis resolution.
Anti-VEGF antibody treatment during resolution led to impaired
tissue repair. Mechanistically, VEGF regulated endothelial per-
meability, monocyte recruitment, and affected the CXCL9 and
MMP13 expression of scar-associated macrophages. Importantly,
depletion of Cfsr1+ cells (including macrophages, monocytes, and
DCs Table 2) impaired fibrosis resolution (112).
Based on these findings, macrophages can be grouped in profi-
brogenic and restorative macrophage populations beyond the
M1/M2 scheme, a classification that might be much more benefi-
cial for finding new targets for fibrosis therapy. However, multiple
open questions remain concerning the balance of the heteroge-
neous population in liver diseases and the relation to each other.
One molecule could provide a better understanding to the prob-
lem, the chemokine CX3CL1. Ramachandran et al. showed a
higher expression of CX3CR1 within the restorative macrophage
population, then in the profibrotic subset (28). Consistent with
these findings, HSC and hepatocyte-derived fractalkine led to the
induction of Arginase 1 in a mixed Kupffer-cell/macrophage cell
population, a marker that has been associated with the fibrolytic
macrophage subset (28, 104). Thus, an intriguing possibility is the
progressive class switch between macrophage populations dur-
ing fibrosis progression and regression. This possibility is under-
lined by the fact that the overall number of profibrogenic Ly6Chi
macrophages strongly decreases in resolution despite the presence
of their strong proliferation activity at early time points of fibrosis
regression. At the same time, the number of Ly6Clo macrophages
increases (28). Along this line, blocking CCL2 dependent liver
infiltration by Ly6Chi monocytes during fibrosis regression leads
to a higher relative amount of Ly6Clo macrophages (113). More-
over, the Ly6Clo macrophages could be shown to be postphagocytic
and seem to appear in the phase of reduced hepatocyte death, fur-
ther supporting the switch concept (28). It remains to be clarified
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in the future how the macrophage populations interact and relate
to each other. Similarly as the murine restorative macrophages
in humans, this population is likely represented by the CD14+
CD16+ cells (24, 26). They display phagocytic activity but as oppo-
site to the murine cells express a variety of pro-inflammatory and
pro-fibrogenic molecules as well.
Besides macrophages, DCs have also been implicated in liver
fibrosis resolution. Jiao et al. have demonstrated that depletion of
CD11c+ cells leads to delay in fibrosis resolution and delayed clear-
ance of activated HSCs. To more precisely pinpoint DCs in this
process, adoptive transfer of purified DCs or expansion of endoge-
nous DCs using FLT3L could accelerate regression. Moreover, DCs
were the source of MMP9 and therefore seem to complement
restorative macrophages in this process (75).
NON-ALCOHOLIC FATTY LIVER DISEASE
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifes-
tation of metabolic syndrome that includes hypertension, hyper-
lipidemia, insulin resistance, and visceral adiposity, and shows a
worldwide increasing tendency among chronic liver diseases (114,
115). In most cases, the liver steatosis is mild. However, up to one-
fifth of the cases progresses toward NASH that is characterized
by intrahepatic inflammation, increased steatosis with hepatocel-
lular ballooning, and often accompanied by progressive fibrosis
(114, 115). NASH is prone to the development of cirrhosis and
liver cancer (115). While the precise cellular and molecular mech-
anisms of NASH are not yet fully understood, multiple studies
have investigated macrophages and DCs in this disease.
Similarly as during liver fibrogenesis, in NASH, the two
main components that show alterations are the response of
macrophages/KCs and the recruited inflammatory monocytes.
The key role of macrophages/KCs in NASH has been demon-
strated in studies where these cells were specifically depleted using
gadolinium chloride or clodronate liposomes (81–83, 85). In the
absence of KCs, the steatohepatitis was markedly reduced. In addi-
tion to this, KCs display an M1 TNF expressing pro-inflammatory
phenotype and increase triglyceride accumulation, decrease fatty
acid oxidation and insulin responsiveness of hepatocytes (82, 83).
KC-derived TNF production seems to be central in NASH devel-
opment, as silencing liver TNF or using TNFR1/2 deficient animals
attenuate liver steatosis compared with control wild-type animals
(85, 116).
Multiple triggers have been identified for KC activation and
for the induction of their pro-inflammatory cytokine production
in NASH. TLR4 deficient animals showed reduced liver damage
and KC depletion prevented the increase in TLR4 expression dur-
ing MCD diet (81). Bacterial product induced KC activation is in
accordance with clinical data that demonstrate bacterial transloca-
tion in NASH patients (117). Notably, TLR4 can be triggered not
only by LPS but also by free fatty acids and high mobility group
box-1 protein (HMGB1) that is increased in obesity and during
hepatocyte injury. Not only LPS but also translocated nucleic acids
have been implicated in the development of NASH via triggering
TLR9 mediated KC activation and IL-1β release (118).
Lipidomics and mass spectrometry profiling revealed that KCs
accumulate toxic lipids due to the dysregulation of lipid metab-
olism during high fat diet. Moreover, these lipid-loaded KCs
produce pro-inflammatory cytokines and chemokines (119). The
balance between the M1 and M2 type of KCs seem to be a key
for NASH progression. Mice fed with high-fat diet displayed a
predominant M2 KC polarization, the apoptosis of M1 KCs and
resistance to hepatocyte steatosis. In vitro experiments demon-
strated that M2 macrophages release IL-10 that in return increase
the sensitivity of M1 macrophages to undergo apoptosis (120).
The other hallmark of NASH is the increased monocyte recruit-
ment to the injured liver. Activated KCs upregulate their MCP-1
expression that is the major chemokine involved in the recruit-
ment of Ly6Chi cells. These Ly6Chi cells are pro-inflammatory
and further perturb hepatic inflammation (85). Consequently,
CCR2 deficient animals show decreased steatosis (113, 121). On
the other hand, CCR2 signaling, when MCD diet is replaced with
control diet, counteracts tissue resolution by perpetuating inflam-
mation (113). This is a similar phenomenon as observed in fibrosis
resolution (113).
Non-alcoholic steatohepatitis is associated with increased num-
ber of hepatic DCs identified by MHCII+ CD11c+ cells (77).
Depletion of these cells using CD11c-DTR mouse model exacer-
bates hepatic inflammation whereas during the resolution phase
delays the reconstitution of normal tissue homeostasis. Impor-
tantly, these cells take up apoptotic cells, inhibit TLR expression,
T cell expansion, and cytokine production by innate cells (77).
This strongly suggests DCs as an important negative regulator of
NASH inflammation. As opposite to this, another study has clas-
sified CD11c+ cells during MCD-diet based on their lipid content
(43). It remains to be clarified whether the tolerogenic LL-DC (low
lipid DC) population is equivalent with the same immunoregula-
tory DCs in NASH as described by Henning et al. Of note, based
on the surface marker expression profile of HL-DCs and LL-DCs,
they rather seemed to be a part of a heterogeneous population,
despite that all cells expressed various level of CD11c (43).
SUMMARY AND CONCLUSION
Taken together, the liver represents a unique immunological niche
within the body. Its parenchymal and non-parenchymal cells
guard its tolerogenic and suppressive microenvironment while
supporting its sentinel task of the portal and systemic circu-
lation (Figure 1). Most liver injuries trigger the activation of
resident KC/macrophage population that rapidly releases pro-
inflammatory mediators such as TNF and IL-1β. This is followed
by a chain of events that seem to be commonly shared by many
injuries causing NASH and leading to liver fibrosis. The response
involves the alterations within the myeloid cell composition pri-
marily affecting macrophages. Importantly, other immune cells
such as DCs, neutrophils, innate cells, and activated T cell are also
recruited to the injured liver and play various roles in disease pro-
gression (6, 97). The exact role of liver DCs during chronic liver
injury is yet to be determined. Nevertheless, they seem to be sim-
ilarly pro-inflammatory as the Ly6Chi recruited monocytes. This
feature is shared with infectious liver diseases; thus, it supposes to
induce liver protecting immunity (2, 7). During chronic liver dis-
eases, the overwhelming presence of pro-inflammatory immune
cells together with liver damaging noxious agents eventually lead
to extensive cell death and scar formation, a common outcome for
chronic liver disorders. While KC activation alarms other immune
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FIGURE 1 |The contribution of DCs and macrophages to the
pathomechanism of liver fibrosis and NASH. Liver injury triggers the
activation of Kuppfer cells, the resident macrophage population of the liver.
Their activation leads to the release of inflammatory mediators and
chemokines such as TNF, IL-1β, and CCL2. This is followed by the recruitment
of various immune cells involving inflammatory monocytes and DCs. The
Ly6Chi monocytes differentiate into M1 CCR9+ iNOS+ macrophages, and
together with DCs in the progression phase of liver injury, act in a
pro-inflammatory manner and perpetuate inflammation. Some DCs, possibly
the LL-DCs, seem to inhibit liver steatohepatitis and protect liver damage. In
resolution, the Ly6Clow restorative macrophages together with MMP9+ DCs
promote fibrolysis and the restoration of normal tissue architecture. HMGB-1,
high mobility group box-1 protein; HSC, hepatic stellate cells; KC, Kupffer
cells; LL-DC, low lipid containing DCs; LSEC, liver sinusoidal endothelial cells.
cells to travel to the liver, it influences metabolic processes and
survival of hepatocytes. During disease progression, Ly6Chi cells
seem to develop into Ly6Clo restorative macrophages. These cells,
if the harmful agent vanishes, lead to resolution and can restore
normal tissue architecture (Figure 1). Especially, in this process,
DCs are complementing the macrophage population. In infection,
recent report demonstrated that necroptosis of KCs was necessary
to induce the Th2 mediated tissue repair (106) that remains to be
tested to affect fibrosis resolution in the future. Equally important
is the more detailed understanding of the factors involved in the
switch from the pro-inflammatory to the restorative macrophage
population.
Despite of the significant amount of data available in mice,
we have just limited understanding about the course of events in
human liver diseases. It will need future studies to analyze DC,
monocyte, and macrophage populations within human liver sam-
ples not only phenotypically and functionally but also on genomic
level in comparison with their murine counterparts. This can
lead to better understanding of liver diseases but also for iden-
tifying novel therapeutic targets. A promising clinical perspective
is to target chemokines in the early phase of the liver response to
avoid inflammatory cell recruitment and further inflammation.
One possibility is affecting the CCL2 axis. Currently, Cenicriviroc,
an inhibitor of CCR2, is tested (Centaur study, phase 2 clin-
ical trial, NCT:022117475) to attenuate fibrosis progression in
NASH patients. Along this line, other chemokines that could affect
the differentiation of monocytes to inflammatory macrophages
could be a possible target in the future. Additionally, DCs and
restorative macrophages could become novel objectives for induc-
ing fibrolysis and reversing liver damage. Notably, autologous
transfer of expanded mononuclear cells to chronic viral hepatitis-
associated fibrotic patients showed improved outcome as indicated
by reduced Child-Pugh score (122), suggesting a great potential of
myeloid cell transfer-based therapeutic procedures in the future.
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